Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473592 | 0.86 | MEN1 (0.55) | MEN1KMT2AMAPTTDP1TP53 | |
| SCHEMBL6289218 | 0.79 | TP53 (0.60) | MEN1KMT2AMAPTTP53 | |
| SCHEMBL6287582 | 0.79 | TP53 (0.60) | MEN1KMT2AMAPTTP53 | |
| SCHEMBL4856275 | 0.79 | TP53 (0.60) | MEN1KMT2AMAPTTP53 | |
| SCHEMBL21473591 | 0.78 | MAPT (0.47) | MEN1KMT2AMAPTTDP1TP53 | |
| SCHEMBL15146902 | 0.76 | KMT2A (0.55) | MEN1KMT2AMAPTTDP1POLB | |
| SCHEMBL24369041 | 0.75 | KMT2A (0.54) | MEN1KMT2AMAPTTDP1POLB | |
| SCHEMBL24369040 | 0.75 | KMT2A (0.54) | MEN1KMT2AMAPTTDP1POLB | |
| SCHEMBL24369039 | 0.75 | KMT2A (0.54) | MEN1KMT2AMAPTTDP1POLB | |
| SCHEMBL31252800 | 0.75 | KMT2A (0.54) | MEN1KMT2AMAPTTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-05-27 | — | — | US | disclosed |
| EP-3778586-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | East China University of Science and Technology (CN) | 2021-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EGFR, ERBB2, ERBB4 | MEN1 4480/4885KMT2A 3689/4885MAPT 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.